Astellas urges the Centers for Medicare and Medicaid Services to reconsider rule on physician incentive payments

Jun 28, 2016
Astellas urges the Centers for Medicare and Medicaid Services to reconsider rule on physician incentive payments

On June 27, 2016, Astellas submitted to the Centers for Medicare and Medicaid Services (CMS) comments on the agency’s proposed rule on the Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive Under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models.

Our comments outline a number of concerns with the proposal and urge the agency to reconsider the proposed rule, including:

  • The proposed rule needs refinements to focus better on specialty physicians
  • CMS should strongly encourage NQF endorsement of MIPS and APM quality measures
  • CMS should emphasize patient-reported outcome measures in quality evaluations
  • CMS should proceed cautiously before incorporating Part D drug costs into the MIPS resource use performance category
  • CMS should encourage collaborative arrangements between manufacturers and providers

Please find our full comments here.

Astellas urges the Centers for Medicare and Medicaid Services to reconsider rule on physician incentive payments

Karl Uhlendorf is director of communications and stakeholder engagement at Astellas Pharma US, Inc. With a 20-year track record of leading diverse public affairs and editorial teams, he currently oversees Astellas’ government communications and stakeholder engagement program.

Prior to joining Astellas in 2014, Karl was vice president of communications and public affairs at the Pharmaceutical Research & Manufacturers of America (PhRMA), responsible for communications strategy and execution in support of the association’s federal and state advocacy priorities. During his eight years at PhRMA, he assumed roles of increasing responsibility and scope.

Prior to joining PhRMA, Karl was editorial director at FDC Reports/Elsevier Business Intelligence, publisher of “The Pink Sheet” and other leading trade publications dedicated to FDA-regulated industries. He began his career as a reporter covering biomedical research and health policy, parlaying the experience into a series of editorial leadership positions.

Karl is actively engaged with a wide array of health-related organizations, including PhRMA, the Biotechnology Innovation Organization, National Pharmaceutical Council, National Consumers League, HealthyWomen, WomenHeart, Research!America and Caregivers Action Network. He graduated with a Bachelor of Literature degree from Bates College in Lewiston, Maine.

Leave a Reply